Intravitreal Aflibercept for AMD: 2-year Results: The VIEW 1 and 2 studies showed high degrees of safety and efficacy at 2 years

Retina Today

Volumn , Issue MARCH 2012, 2012, Pages 49-51

  Heier, Jeffrey S ^a  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859395480     PISSN: None     EISSN: 18250572     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Williams GA. The -25 Modifier: When and Why? Retina Today. February 2012.
2. Eylea [package insert]. Tarrytown, NY: Regeneron; 2011. http://www.regeneron.com/Eylea/eylea-fpi.pdf. Accessed February 16, 2012.
3. Regeneron announces FDA approval of EYLEA (aflibercept) injection for the treatment of wet age-related macular degeneration [press release]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; November 18, 2011.
4. Lucentis [package insert]. South San Francisco, CA: Genentech; 2010. http://www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf. Accessed February 16, 2012.
5. Heier JS. Aflibercept Update 2. Paper presented at: Macula 2012; January 20-21, 2012; New York, NY.
6. Nguyen QD, Heier J, Brown D, et al. Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF trap-eye in wet AMD: one-year results of the View-1 study Invest Ophthalmol Vis Sci. 2011;52:E-Abstract 3073.
7. Schmidt-Erfurth U, Chong V, Kirchof B, et al. Primary results of an international phase III study using intravitreal VEGF trap-eye compared to ranibizumab in patients with wet AMD (VIEW 2). Invest Ophthalmol Vis Sci. 2011;52:E-Abstract 1650.
8. Two year results of phase 3 studies with EYLEA (aflibercept) injection in wet AMD show sustained improvement in visual acuity [press release]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; December 5, 2011.
9. Heier JS. VEGF Trap-Eye vs ranibizumab for neovascular AMD: results from 2457 patients in the phase 3 VIEW 1 and VIEW 2 studies. Paper presented at: Retina Society Annual Meeting; September 22-25; Rome, Italy.
10. Heier JS. Vascular endothelial growth factor (VEGF) trap-eye, 1-year results. Paper presented at: The American Society of Retinal Specialists; August 20-24, 2011; Boston.